We are pleased to welcome you on Rompharm Company site.
We started our activity in 2004 with the first GMP approved facility consisting of two production lines: one for sterile solutions/suspensions (eye drops) and the second for non sterile solutions/suspensions (oral drops, nasal drops/spray, topic solution/spray). The production capacity of these two lines allows the release of 30 million units per year. Because of increasing market demands, Rompharm Company had purchased high technology equipments achieving the production capacity of 64 million units yearly.
In September 2006 we put into operation the second GMP approved facility for solid dosed forms. Our state of the art equipment allows us to produce powders, granules or pellets conditioned in capsules, sachets or bottles (dry syrups).
To further extend our product range in December 2007 we had started the third facility for injection solutions aseptically produced, with a capacity of 100 million ampoules per year.
Rompharm Company gladly announces the commissioning of its new state of the art facility for manufacturing of prefilled syringes and solutions for perfusion. The prefilled syringes line with an output of more than 100 million units per year is suitable for a wide range of filling volumes ranging from 0.3ml to 20ml. The line for perfusions in glass containers with an output of more than 20 million units per year manages volumes ranging from 2ml to 250ml.
Rompharm’s philosophy is oriented to product quality, compliance with GMP, along the whole manufacturing and distribution processes. and other in force regulation (EC Directive 2003/94/EC). Accomplishment of requirements is based upon modern technologies implementation together with a complex system of Quality assurance and validation as a whole. One of the main elements for the maintenance of the quality system is the personnel. Their skills, the creative potential are more valuable than the assets and equipment. That is why each employee of Rompharm Company is an integral part of the quality assurance system.
The range of products released by Rompharm Company is directed on the real and potential capacity of the market, on the level and prospects of demands. Most of our products are generic medicines. The marketing efforts to increase the sales are directed to the medical representatives; it is realized due to company’s own network in CIS countries and the relation organized with local distributors. As regards the prices and quality for the released products, we can certainly say that they are competitive in comparison with already available analogues.
Rompharm Company is working to increase the range of products, to expand the sales to EU market in cooperation with strategic partners, as a consequence of political and economical processes in Romania.
Rompharm Company looks optimistically towards establishing commercial relations with distributors of pharmaceutical products and is opened for long-lasting mutual collaborations.